Presentations at ESMO Immuno-Oncology Virtual Congress build case for CLEVER-1 as a new immune checkpoint target
Data from ongoing PhI/II MATINS trial showcasedRole of myeloid cells in shaping the tumour microenvironment highlightedCompany announcement, 10 December 2020 at 9.00 AM (EET)TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that two presentations at the European Society of Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 will showcase data from the Company’s PhI/II MATINS study and explore the role of myeloid cells in shaping the tumour microenvironment (TME). ‘CLEVER-1 a new immune